Membership Special - Pituitary and Thyroid Diseases-Clinical Advances in Pituitary Diseases

Video Transcription

Video Summary

In this video, Dr. Bettina Winzler presents a study on the use of glucagon-like peptide 1 receptor agonists in primary polydipsia, a condition characterized by excessive fluid intake. The study aimed to explore whether these medications could reduce fluid intake and thirst in patients with primary polydipsia. The study was a randomized, placebo-controlled, double-blind crossover trial, with participants undergoing a three-week treatment phase on either placebo or dulaglutide, a GLP-1 receptor agonist. The primary outcome measure was total fluid intake during an eight-hour evaluation visit, with secondary measures including thirst perception, reported average daily fluid intake, and urinary frequency. The results showed that patients on dulaglutide had a significant reduction in fluid intake compared to placebo, with a relative reduction of 17%. Thirst perception was also significantly reduced in patients on dulaglutide. The study suggests that GLP-1 receptor agonists may be a potential treatment option for primary polydipsia, reducing excessive fluid intake and improving thirst perception. Further research is needed to explore the optimal dosage and long-term effects of GLP-1 receptor agonists in this condition.

Keywords

glucagon-like peptide 1 receptor agonists

primary polydipsia

excessive fluid intake

fluid intake reduction

thirst perception

dulaglutide

GLP-1 receptor agonist

randomized controlled trial

placebo-controlled study

urinary frequency


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274